NDRA Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
1.5M
-31.8%
2.2M
+34.0%
1.6M
+18.3%
1.4M
+5.4%
1.3M
R&D
233.7K
-69.9%
776.4K
+52.8%
508.1K
+17.6%
432.1K
+13.4%
381.1K
SG&A
1.2M
-10.6%
1.4M
+25.4%
1.1M
+18.7%
938.6K
+2.0%
920.0K
Operating Income
-1483256
+31.8%
-2173748
-34.0%
-1622026
-18.3%
-1370703
-5.4%
-1301090
EBITDA
-1475100
+31.8%
-2164256
-44.4%
-1498660
-10.2%
-1359917
-5.3%
-1291734
Net Income
159.9K
+112.2%
-1311433
+58.6%
-3169209
-98.6%
-1595959
-30.2%
-1225912
EPS (Basic)
$0.12
+111.0%
$-1.09
+61.8%
$-2.85
-35.7%
$-2.10
-22.8%
$-1.71
EPS (Diluted)
$0.06
+105.5%
$-1.09
+61.8%
$-2.85
-35.7%
$-2.10
-22.8%
$-1.71
Shares (Diluted)
2.5M
+106.3%
1.2M
+7.9%
1.1M
+46.1%
761.2K
+6.2%
717.1K
ENDRA Life Sciences (NDRA) โ€” Financials